Patent ID: 9682129
Date: 2017-06-20
CPC Classifications: A61K,A61P,C12N,C12Y

Claim:
1. A method of treating cognitive impairment associated with Hunter Syndrome comprising; a) determining cognitive functions in a subject having Hunter Syndrome by DAS-II testing to provide a control general concept ability (GCA) score; b) administering intrathecally to a said subject a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose of greater than 10 mg and an administration interval for a treatment period longer than 6 months; c) determining cognitive functions in said subject during and/or after the treatment period by DAS-H testing to provide a treatment general concept ability score, wherein cognitive impairment is treated when cognitive impairment is improved, stabilized or reduced decline of cognitive function as measured by the comparison of the general conceptual ability (GCA) scores.